The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Triplebodies for AML: origin, rationale & development
Georg Fey
• 15 Mar 2019
Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the origin and rationale behind triplebodies, as well as giving an overview of triplebody agents in development. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.
